Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-&kgr;B Activation

Incretin therapies have received much attention because of their tissue-protective effects, which extend beyond those associated with glycemic control. Cancer is a primary cause of death in patients who have diabetes mellitus. We previously reported antiprostate cancer effects of the glucagonlike peptide-1 (GLP-1) receptor (GLP-1R) agonist exendin-4 (Ex-4). Breast cancer is one of the most common cancers in female patients who have type 2 diabetes mellitus and obesity. Thus, we examined whether GLP-1 action could attenuate breast cancer. GLP-1R was expressed in human breast cancer tissue and MCF-7, MDA-MB-231, and KPL-1 cell lines. We found that 0.1 to 10 nM Ex-4 significantly decreased the number of breast cancer cells in a dose-dependent manner. Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation significantly and dose-dependently. However, the dipeptidyl peptidase-4 inhibitor linagliptin did not affect breast cancer cell proliferation. When MCF-7 cells were transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo. Ki67 immunohistochemistry revealed that breast cancer cell proliferation was significantly reduced in tumors extracted from Ex-4-treated mice. In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression. Furthermore, Ex-4 decreased both Akt and IκB phosphorylation. These results suggest that GLP-1 could attenuate breast cancer cell proliferation via activation of GLP-1R and subsequent inhibition of NF-κB activation.

[1]  C. Tseng.  Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes , 2017, Clinical breast cancer.

[2]  T. Nakayama,et al.  Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus , 2017, Journal of diabetes investigation.

[3]  T. Yanase,et al.  GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control , 2016, Expert review of endocrinology & metabolism.

[4]  Y. Dodurga,et al.  Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells , 2016, Tumor Biology.

[5]  A. Dear,et al.  Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis , 2016, Diabetes & vascular disease research.

[6]  T. Yanase,et al.  Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth , 2015, PloS one.

[7]  D. Drucker.  Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture , 2015, Diabetes.

[8]  J. Zhan,et al.  Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway , 2014, Cardiovascular Diabetology.

[9]  T. Yanase,et al.  Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth , 2014, Diabetes.

[10]  T. Zhu,et al.  Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. , 2014, International immunopharmacology.

[11]  A. Goto,et al.  Report of the JDS/JCA Joint Committee on Diabetes and Cancer , 2013, Diabetology International.

[12]  A. Goto,et al.  Latest insights into the risk of cancer in diabetes , 2013, Journal of diabetes investigation.

[13]  L. Wang,et al.  Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway , 2013, Journal of Endocrinological Investigation.

[14]  T. Yanase,et al.  The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis , 2013, Diabetology & Metabolic Syndrome.

[15]  A. Thotakura,et al.  Cancer: NF-κB regulates energy metabolism. , 2012, The international journal of biochemistry & cell biology.

[16]  T. Ninomiya,et al.  Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. , 2012, American journal of epidemiology.

[17]  D. Giugliano,et al.  Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.

[18]  Raj Kumar,et al.  Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. , 2012, Cancer letters.

[19]  H. Hsieh-Li,et al.  Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection , 2012, PloS one.

[20]  M. Haimsohn,et al.  The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells , 2012, Breast Cancer Research and Treatment.

[21]  T. Yanase,et al.  Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. , 2012, Diabetes research and clinical practice.

[22]  Afsar Barlas,et al.  GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. , 2012, Endocrinology.

[23]  N. Mikhail.  Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. , 2011, Current drug safety.

[24]  D. Drucker,et al.  Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. , 2011, Endocrinology.

[25]  W. L. Jin,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. , 2011, Biochemical and biophysical research communications.

[26]  S. Shoelson,et al.  Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.

[27]  S. Ghosh,et al.  NF-κB, inflammation, and metabolic disease. , 2011, Cell metabolism.

[28]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[29]  J. Bunt,et al.  The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study , 2009, Diabetologia.

[30]  Y. Isaka,et al.  Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus , 2008, Journal of clinical pharmacology.

[31]  M. Tschöp,et al.  Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. , 2007, The Journal of clinical investigation.

[32]  A. Fukamizu,et al.  Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor* , 2007, Journal of Biological Chemistry.

[33]  R. Kawamori,et al.  The NR4A Orphan Nuclear Receptor NOR1 Is Induced by Platelet-derived Growth Factor and Mediates Vascular Smooth Muscle Cell Proliferation* , 2006, Journal of Biological Chemistry.

[34]  P. Reaven,et al.  Molecular and signaling mechanisms of atherosclerosis in insulin resistance. , 2006, Endocrinology and metabolism clinics of North America.

[35]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[36]  A. Scheen,et al.  Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. , 2004, Diabetes care.

[37]  D. Drucker.  Enhancing incretin action for the treatment of type 2 diabetes. , 2003, Diabetes care.

[38]  M. Kurosumi,et al.  A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice. , 1995, British Journal of Cancer.

[39]  S. Robbins,et al.  The Cause of Death in Diabetes , 1944 .

[40]  Luis C L Correia,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[41]  P. Butler,et al.  Glucagon like peptide-1 receptor expression in the human thyroid gland. , 2012, The Journal of clinical endocrinology and metabolism.

[42]  白木 綾.  The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells , 2012 .

[43]  V. Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[44]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.

[45]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .